Fig. 2

Different doses of smTRAIL have different immunomodulatory functions. A Experimental layout. Three days after the treatment, 4T1 and CT26 tumor tissues were obtained for immune cell analysis by flow cytometry. B Short-term tumor growth curve of smTRAIL treatment (n = 13). C 4T1 and CT26 tumors analyzed by flow cytometry to calculate the percentages of intratumoral lymphocytes (CD45⁺), CD4⁺ T cells (CD45⁺CD4⁺), activated CD4⁺ T cells (CD45⁺CD4⁺CD69⁺), CD8⁺ T cells (CD45⁺CD8⁺), activated CD8⁺ T cells (CD45⁺CD8⁺CD69⁺/IFNγ⁺), D activated DC cells (CD45⁺CD8⁺CD69⁺), activated NK cells (CD3⁻CD49b⁺CD107a⁺/GzmB⁺), TAMs (CD45⁺F4/80⁺CD11b⁺), M1-TAMs (CD45⁺F4/80⁺CD11b⁺CD86⁺), and M2-TAMs (CD45⁺F4/80⁺CD11b⁺CD206⁺) (n = 5). E CT26 tumor tissues were obtained and the levels of IL-12p70 and IFNγ were analyzed (n = 5). F The expression of IL-10 in CT26 tissues was analyzed by ELISA (n = 5). G The percentages of IL-10⁺CD45⁺ were analyzed (n = 5). H The percentages of IL-10⁺ M2-TAMs were analyzed (n = 5). A two-way ANOVA test was used to compare the tumor growth curves. One-way ANOVA was performed to calculate the significant differences between groups, followed by LSD analysis. *P < 0.05; **P < 0.01; ****P < 0.0001